

Supreme Court: FDA Approval Doesn't Bar Suits

BY ALICIA AULT

In an eagerly anticipated opinion, the U.S. Supreme Court has upheld a lower court ruling that Food and Drug Administration approval does not give pharmaceutical companies immunity from product liability lawsuits.

The justices voted 6-3 to affirm the judgment of the Vermont Supreme Court that federal law did not preempt

Diana Levine's claim of inadequate warning on the label of promethazine (Phenergan). Ms. Levine received the drug by intravenous push and subsequently lost her arm. She was awarded \$6.7 million by a Vermont jury.

A majority of justices rejected the argument by Wyeth Pharmaceuticals Inc., which manufactures Phenergan, that it was impossible for the company to simultaneously comply with both

federal and state laws and regulations.

Wyeth could have unilaterally strengthened the label at any time without input or clearance from the FDA, wrote the justices, concurring with the lower court opinion. And the company's argument that following the duty to warn under state law would have interfered with the FDA's power to preempt state law was "meritless," according to the majority opinion.

Justice Clarence Thomas voted with the majority, agreeing that Wyeth could have changed its label and complied with both state and federal laws. But he said that he did not agree with the majority's more far-reaching conclusions about preemption, specifically a tendency to override state laws when they were perceived to be an impediment to enforcing federal statutes.

Justice Samuel Alito and Justice Antonin Scalia, joined by Chief Justice John Roberts, dissented, writing in their opinion that "this case illustrates that tragic facts make bad law. The Court holds that a state tort jury, rather than the Food and Drug Administration, is ultimately responsible for regulating warning labels for prescription drugs." That premise is not consistent with previous rulings, they wrote.

Indeed, just last year the U.S. Supreme Court ruled in *Riegel v. Medtronic Inc.* that FDA approval conferred special protection against product liability suits involving medical devices.

Consumer advocacy group Public Citizen called the ruling a broad rebuff to the industry's attempt to duck tort damages. Brian Wolfman, director of Public Citizen Litigation Group, said that the organization was "extremely gratified" that the Court "upheld the traditional right of patients harmed by defective and mislabeled drugs to sue drug companies to recover compensation for their injuries." ■

SAVE THE DATE!

REGISTER TODAY FOR THIS
EXCITING SCIENTIFIC PROGRAM

To register or for more information,
visit www.sdefderm.com

THIS ACTIVITY HAS
BEEN APPROVED FOR
24 AMA PRA
Category 1 Credits™

SKIN DISEASE EDUCATION FOUNDATION presents

COSMETIC DERMATOLOGY SEMINAR 2009™

A CONTINUING MEDICAL EDUCATION CONFERENCE

May 28–31, 2009
Loews Santa Monica Beach Hotel

Learn the latest in cosmetic dermatology and get up-to-date on recent breakthroughs in therapeutic treatments and cosmetic surgery. An outstanding faculty, representing the best in the field, will cover the newest techniques, scientific therapies and research focused on improving patient care and enhancing your practice.

Featuring:

- Facial Rejuvenation: The Best Techniques and Devices
- Body Contouring: Assessing What Really Works
- Botulinum Toxins: Does it Matter Which One you Use?
- Filling the Deflated Face: With What?

MEDICAL DIRECTORS:



David J. Goldberg, MD, JD
Clinical Professor, Mount Sinai School of Medicine
Director, Skin Laser & Surgery Specialists of NY/NJ
New York, NY



Christopher B. Zachary, MBBS, FRCP
Professor and Chair, Department of Dermatology
University of California, Irvine, CA

The opinions expressed at Skin Disease Education Foundation seminars do not necessarily reflect those of Skin Disease Education Foundation, Elsevier Inc. or the supporters of the seminars. Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in presentations, including any claims related to the products, drugs or services mentioned.

Jointly sponsored by



SKIN DISEASE
EDUCATION
FOUNDATION
an Elsevier business

www.sdefderm.com

INDEX OF ADVERTISERS

Abbott Laboratories TriLipix	29-32
Accera, Inc. Axona	5
Alcon, Inc. Patanase	33-34
Audio-Digest Corporate	38
Boehringer Ingelheim Pharmaceuticals, Inc. Micardis	25-26
Eisai Inc. and Pfizer Inc. Aricept	18a-18b
Endo Pharmaceuticals Lidoderm	14-16
Forest Laboratories, Inc. Lexapro Namenda Bystolic	21-24 26a-26b 35-36
King Pharmaceuticals, Inc. Flector	36a-36b
Merck & Co., Inc. Januvia	8a-8b
Novo Nordisk Inc. NovoLog Corporate	11-12 17
Pfizer Inc. Lipitor	3-4
Purdue Pharma L.P. OxyContin	7-8
Rexall Sundown, Inc. Osteo Bi-Flex	10
Takeda Pharmaceuticals America, Inc. Uloric	39-40
Wyeth Pharmaceuticals Inc. Pristiq	43-44
Xezo Corporate	18